Dr Shane Olwill | Vice President of Development
Pieris Pharmaceuticals

Dr Shane Olwill, Vice President of Development, Pieris Pharmaceuticals

Dr. Shane Olwill has spent over a decade in oncology focused drug discovery with a specific interest in the development of novel biologics. Prior to joining Pieris, Shane was Director of Research at Fusion Antibodies Ltd where he was responsible for the discovery and development of multiple drug candidates. He is a named inventor on 16 patents and has published his research in many international peer review journals. Shane received his PhD in Molecular Hematology / Oncology from University of Ulster, following which he worked as an industrial postdoc in conjunction with University College Cork. Shane has a PgDip in Management Practice from DIT Business School and is a state qualified Medical Scientist.

Appearances:



World Immunotherapy Congress 2018, Day 1 @ 14:30

PRS-343 (4-1BB / HER2) is a first-in-class T-Cell agonist which drives tumor localized activation of the immune system

  • Rationale for targeting 4-1BB and other costimulatory receptors
  • Preclinical characterisation of PRS-343 as a differentiated 4-1BB agonist
last published: 26/Sep/18 13:15 GMT

back to speakers

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.

 

Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October

Sign Up for Event Updates